Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

.

"These data demonstrate the significant benefits that ACZ885 may provide this young population, both in steroid reduction and in extending the period these children can live free from SJIA flares," said David Epstein, Head of the Pharmaceuticals Division of Novartis. "Novartis is committed to helping improve the health of patients with SJIA and other inflammatory diseases, which is why we are delighted to be sharing these results."

ACZ885 is an investigational fully human monoclonal antibody which neutralizes the key inflammatory mediator, interleukin-1 beta (IL-1 beta), which plays an important role in a number of diseases including SJIA[5].

The incidence of SJIA is estimated to be less than 1 in 100,000 children[6]. It is called 'systemic' because the inflammation affects the whole body, as well as most of the joints[4]. The condition is characterized by potentially life-long, recurrent and painful arthritis flares, skin rashes and daily spiking fevers[2],[4].

Novartis is also presenting a number of other studies at ACR, including a second pivotal Phase III trial of ACZ885 in SJIA, which was previously presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, in September.

About the StudyThe Phase III, two-part study had an open-label, single-arm active treatment in Part I followed by a randomized, double-blind, placebo-controlled, event-driven withdrawal design in Part II[1]. A total of 177 patients between the ages of 1 and 19 years with active SJIA were enrolled in the study[1]. In Part I, patients received a subcutaneous (s.c.) dose of ACZ885 (4 mg/kg, up to 300 mg) every 4 weeks. After 8 weeks, patients who met the adapted ACR Pediatric 30 criteria began tapering (reducing) their steroid use until either: a) the dose had been decreased to less than or equal to 0.5 mg/kg[7] while maintaining the adapted ACR Pediatric 30 Criteria (successful tapering of steroids); or b)
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Personalized Medicine - Scientific ... , The aim of personalized medicine ... drug to the right patient and, in some ... a patient according to his/her genotype. This report ...
(Date:3/3/2015)... , March 3, 2015 ... with tools for implementing competency-based training to comply with ... DirectCourse is offering a new crosswalk tool ... (HCBS) implement competency-based training for direct service workers as ... & Medicaid Services (CMS) regulations. CMS amended ...
(Date:3/3/2015)... , March 3, 2015  PDL BioPharma, Inc. (PDL ... announced that the third of three shareholder lawsuits filed ... prejudice. On February 2, 2015, a securities ... on behalf of a putative class of purchasers of ... al., No. 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily dismissed without ...
(Date:3/2/2015)... March 02, 2015 Shimadzu Scientific Instruments ... present on LCMS and marijuana analysis at the Pittcon ... 8 to 12 at the Ernest N. Morial Convention ... stop by booth 3121 to discuss laboratory challenges with ... innovative, proven products help save time, money and effort ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3
... 2011 TriLink BioTechnologies, Inc. (TriLink) announced that it ... (TATAA) to sell its CleanAmp™ Products. The Scandinavian based ... qPCR courses worldwide, in addition to providing tailor-made products ... innovative approach to Hot Start PCR, TriLink,s CleanAmp™ Product ...
... March 25, 2011 BioNeutral Group, Inc. (OTC Bulletin ... technology-based company, today announced the appointment of Dr. Stephen ... and a medical practitioner in New York State, as ... Director. Dr. Holt is an independent consultant to the ...
... Diagnostic Laboratory, Inc. (HDL, Inc.) and BG Medicine, Inc. (Nasdaq: ... HDL, Inc. will offer galectin-3 testing services based on the ... Galectin-3 Test was recently cleared by the FDA as an ... failure. Elevated galectin-3 levels are associated with an inherently progressive ...
Cached Biology Technology:TriLink Enters Into Distribution Agreement With TATAA Biocenter 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 4
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... OXFORD, Conn. , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: ... growing mobile commerce market, reports on the recent success of the Wocket™ ... Wocket smart wallet was named as one of the ... of the "5 Best Products Launched At CES So Far" by Newseveryday.com ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... Boston, MA (Jan. 18, 2012) The National ... Research Institute, a subsidiary of Mass. Eye and Ear, ... understand the origins of eye allergies (NEI Grant Number ... principal investigator for the project formally entitled "Cellular and ...
... new approach to motion capture technology is offering fresh ... general. Researchers studied three types of tennis serves, ... which creates the highest potential for shoulder injury. ... Annals of Biomedical Engineering , could aid sports training ...
... of microbiologists led by Indiana University researchers has identified a ... single end or pole of the cell instead of uniform, ... that could have implications in the development of new antibacterial ... bacteria such as Escherichia coli and Bacillus ...
Cached Biology News:Markerless motion capture offers a new angle on tennis injuries 2Markerless motion capture offers a new angle on tennis injuries 3Markerless motion capture offers a new angle on tennis injuries 4Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 2Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 3
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
... effectively seals labware. Waterproof, moisture-proof film ... materials. Can be folded repeatedly and ... Stretched lengthwise at 21C (70F), wrapping ... tension is removed, film only partially ...
Biology Products: